

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

Vinculin Antibody

RRID:AB_10559207

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4650, RRID:AB_10559207

Antibody Information

URL: http://antibodyregistry.org/AB_10559207

Proper Citation: Cell Signaling Technology Cat# 4650, RRID:AB_10559207

Target Antigen: Vinculin

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: Vinculin Antibody

Description: This polyclonal targets Vinculin

Target Organism: dg, rat, h, canine, m, mouse, r, non-human primate, human, mk

Antibody ID: AB_10559207

Vendor: Cell Signaling Technology

Catalog Number: 4650

Alternative Catalog Numbers: 4650S

Record Creation Time: 20231110T071844+0000

Record Last Update: 20260829T051303+0000

Ratings and Alerts

No rating or validation information has been found for Vinculin Antibody.

No alerts have been found for Vinculin Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 90 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Plucińska K, et al. (2026) Cell-type-specific proximity labeling of organ secretomes reveals energy balance-dependent proteomic remodeling. *Cell reports*, 45(6), 117507.

Fanti M, et al. (2026) Methionine-supplemented longevity diet increases growth hormone, GLP-1, and FGF21; reduces frailty; and promotes healthspan. *Cell metabolism*, 38(8), 1579.

Asada S, et al. (2026) Disruption of microhomology-mediated end joining in Ewing sarcoma. *Molecular cell*.

Plucińska K, et al. (2026) Cell type-specific proximity labeling of organ secretomes reveals energy balance-dependent proteomic remodeling. *bioRxiv : the preprint server for biology*.

Odeniyide P, et al. (2026) Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma. *Cancer research*, 86(10), 2508.

Onimus A, et al. (2026) Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion. *Cell reports. Medicine*, 7(5), 102788.

Mödl B, et al. (2026) TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis. *Cancer research*, 86(1), 80.

Tang H, et al. (2026) Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2. *Journal of medicinal chemistry*, 69(13), 15317.

Jack CE, et al. (2026) Investigation into ligand selectivity and bias at the formyl peptide receptor family. *The Journal of pharmacology and experimental therapeutics*, 393(1), 103764.

Kittane S, et al. (2026) The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer. *Cancer research*, 86(5), 1113.

Rosen JC, et al. (2026) Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms. *British journal of cancer*, 134(1), 165.

Mesquita M, et al. (2026) Hypomorphic biliverdin reductase a mutations define bilirubin anti-malarial threshold. *iScience*, 29(6), 115958.

Xiong X, et al. (2025) SENP3 protects hepatocyte from pyroptosis during acute liver injury through deSUMOylation of HNRNPL. *iScience*, 28(8), 113067.

Diegel CR, et al. (2025) The class A repeats of LRP5 are required for normal development of bone, retinal vasculature and mammary gland in vivo. *Disease models & mechanisms*, 18(11).

Xiao T, et al. (2025) RAD23B acquires a copper metalloadaptor function in amphibian-to-reptile evolution to increase metabolism and regulate genomic integrity. *Molecular cell*, 85(18), 3443.

An J, et al. (2025) Integration of metabolomic and transcriptomic analyses reveals regulatory functions of the ChREBP transcription factor in energy metabolism. *Cell reports*, 44(2), 115278.

Park JH, et al. (2025) Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. *Cell reports. Medicine*, 6(2), 101941.

Zhao HY, et al. (2025) An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment. *Cell chemical biology*, 32(2), 280.

Chang J, et al. (2025) Single-cell multi-stage spatial evolutionary map of esophageal carcinogenesis. *Cancer cell*, 43(3), 380.

Garcia GL, et al. (2025) Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. *Cancer discovery*, 15(6), 1203.